Intervention

Bifeprunox

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting0

Common conditions3

Lead sponsors shown3

Clinical trials

9 shown

Efficacy of Bifeprunox in Patients With SchizophreniaNCT00704509 · 2008-06-01

Efficacy of Bifeprunox in Patients With SchizophreniaNCT00658645 · 2008-03-01

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic PatientsNCT00396214 · 2007-04-01

Study Evaluating Bifeprunox in Patients With Schizophrenia.NCT00366327 · 2007-01-01

Open Label Extension Study of BifeprunoxNCT00366171 · 2006-11-01

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar DisorderNCT00139919 · 2006-01-01

Bifeprunox Extension to Extension Study in Patients With SchizophreniaNCT00861497 · 2006-01-01

Twice Daily Titration Study of Bifeprunox in Subjects With SchizophreniaNCT00139906 · 2005-08-01

To Evaluate the Impact of Treatment Interruption on Re-initiation of BifeprunoxNCT00141479 · 2005-05-01

Common conditions

Schizophrenia9 Schizoaffective Disorder3 Bipolar Disorder1

Leading sponsors

Solvay Pharmaceuticals4 H. Lundbeck A/S3 Wyeth is now a wholly owned subsidiary of Pfizer2

Trial status mix

TERMINATED5

COMPLETED4

Phase mix

PHASE36

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.